Evotec SE has announced scientific progress within its neuroscience collaboration with Bristol Myers Squibb Co., with a target-based program now advancing into late preclinical development. This milestone triggers a research payment of $20 million to Evotec.
Calidi Biotherapeutics Inc. has announced a collaboration with Siga Technologies Inc. to support the development of Calidi’s systemic and targeted Rtnova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.
Epiendo Pharmaceuticals ehf and Alveolix AG have achieved significant milestones in their collaboration to advance the treatment of ulcerative colitis.
Aurobac Therapeutics SAS, a biopharmaceutical company founded by Boehringer Ingelheim Pharma GmbH & Co KG, Biomérieux SA and Evotec SE, has announced its strategy to target bacterial infections, antimicrobial resistance and their consequences in acute hospital settings, such as hospital-acquired and ventilator-associated bacterial pneumonia and sepsis.
Tetra Pharm Technologies ApS and Kvanctify ApS have entered into a strategic partnership to accelerate the identification and development of novel drug candidates targeting the endocannabinoid system.
Cartography Biosciences Inc. announced it has entered into a multiyear, strategic collaboration agreement with Gilead Sciences Inc. to discover and develop therapies for patients with triple-negative breast cancer and adenocarcinoma.
Degron Therapeutics Inc. has entered into a collaboration and exclusive license agreement with Takeda Pharmaceutical Co. Ltd. to discover and develop novel molecular glue degraders for multiple targets in oncology, neuroscience and inflammation.
Achilles Therapeutics plc has established a research collaboration with Arcturus Therapeutics Holdings Inc. to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines targeting clonal neoantigens.
Spybiotech Ltd. has entered into a sponsored research agreement with the University of Oxford for the development of a vaccine against Epstein-Barr virus (EBV).
Evergreen Theragnostics Inc. has entered into a collaboration and licensing agreement with the Medical University of Innsbruck (MUI) to advance the development of novel radiopharmaceuticals.
RSS
